Regeneron to buy cancer therapeutics company Checkmate for $250m
With the acquisition, Regeneron will obtain Checkmate’s lead candidate vidutolimod, an investigational, advanced generation CpG-A oligodeoxynucleotide Toll-like receptor…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
20 Apr 22
With the acquisition, Regeneron will obtain Checkmate’s lead candidate vidutolimod, an investigational, advanced generation CpG-A oligodeoxynucleotide Toll-like receptor…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
14 Apr 22
Antares’ commercial products and the current autoinjector expertise will help accelerate Halozyme’s approach to drive durable revenue growth…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
14 Apr 22
The proposed acquisition is in line with GSK’s plans to build a strong portfolio of new speciality medicines…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
08 Apr 22
The proposed acquisition will boost Pfizer’s expertise in infectious disease research and development by providing a complementary approach…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
04 Apr 22
The Indian pharmaceutical company will obtain the Cidmus trademark in India and is allowed to use the Cidmus…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
01 Apr 22
The investment in mAbxience will strengthen the company’s footprint in biopharmaceuticals, and the acquisition of Ivenix will enable…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
31 Mar 22
Neuron23 will use the funding to advance its lead programmes against LRRK2 and TYK2, strengthen its clinical development…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
29 Mar 22
The Japanese regulator’s approval was based on results from global Phase 3 HELP study, Phase 3 HELP OLE…
24 Mar 22
The US agency has also approved complementary diagnostic imaging agent Locametz, to identify patients eligible for treatment using…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
22 Mar 22
Exposure to nitrosamines above Acceptable Daily Intake (ADI) levels for prolonged durations is believed to increase the risk…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates